Paul Thomen

Thursday, 21 November 2013

Top Report on 2022 Type 2 Diabetes – US Drug Industry Analysis

The report “PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022″ by Global Data is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Diabetes Drugs’ market research reports has a new addition of “PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022” on RnRMarketResearch.com.

Summary

 “PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022″. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

Request a sample copy of this report by Global Data @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=131476 .

A dip in sales caused by Actos patent expiry in 2012 and three insulin products’ patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta’s patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining with Victoza and Bydureon overtaking its shares.

Scope

·   Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
·   Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
·   Sales forecast for the top drugs in the US from 2012-2022.
·   Analysis of the impact of key events as well the drivers and restraints affecting the US type 2 diabetes market.

Complete report Spread across [220 Pages] is available @ http://www.rnrmarketresearch.com/pharmapoint-type-2-diabetes-us-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy

·   Understand and capitalize by identifying products that are most likely to ensure a robust return
·   Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
·   Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
·   Make more informed business decisions from insightful and in-depth analysis of drug performance
·   Obtain sales forecast for drugs from 2012-2022 in the US

For further information on PharmaPoint: Type 2 Diabetes – US Drug Forecast and Market Analysis to 2022 ” report OR for any other business research / market intelligence need on the ‘Diabetes Drugs ’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/diabetes-drugs .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.


No comments:

Post a Comment

Note: only a member of this blog may post a comment.